These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 9654064)

  • 21. Plasminogen activator inhibitor type 1 promotes the self-association of vitronectin into complexes exhibiting altered incorporation into the extracellular matrix.
    Minor KH; Peterson CB
    J Biol Chem; 2002 Mar; 277(12):10337-45. PubMed ID: 11796716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The urokinase receptor is a major vitronectin-binding protein on endothelial cells.
    Kanse SM; Kost C; Wilhelm OG; Andreasen PA; Preissner KT
    Exp Cell Res; 1996 May; 224(2):344-53. PubMed ID: 8612711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural and functional characterization of vitronectin-derived RGD-containing peptides from human hemofiltrate.
    Ständker L; Enger A; Schulz-Knappe P; Wohn KD; Germer M; Raida M; Forssmann WG; Preissner KT
    Eur J Biochem; 1996 Oct; 241(2):557-63. PubMed ID: 8917456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitronectin.
    Schvartz I; Seger D; Shaltiel S
    Int J Biochem Cell Biol; 1999 May; 31(5):539-44. PubMed ID: 10399314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cluster of basic amino acids in vitronectin contributes to its binding of plasminogen activator inhibitor-1: evidence from thrombin-, elastase- and plasmin-cleaved vitronectins and anti-peptide antibodies.
    Gechtman Z; Belleli A; Lechpammer S; Shaltiel S
    Biochem J; 1997 Jul; 325 ( Pt 2)(Pt 2):339-49. PubMed ID: 9230112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2.
    Stefansson S; Lawrence DA; Argraves WS
    J Biol Chem; 1996 Apr; 271(14):8215-20. PubMed ID: 8626514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
    Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interactions of plasminogen activator inhibitor-1 with vitronectin involve an extensive binding surface and induce mutual conformational rearrangements.
    Blouse GE; Dupont DM; Schar CR; Jensen JK; Minor KH; Anagli JY; Gårdsvoll H; Ploug M; Peterson CB; Andreasen PA
    Biochemistry; 2009 Mar; 48(8):1723-35. PubMed ID: 19193026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.
    Schroeck F; Arroyo de Prada N; Sperl S; Schmitt M; Viktor M
    Biol Chem; 2002; 383(7-8):1143-9. PubMed ID: 12437099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New insights into the size and stoichiometry of the plasminogen activator inhibitor type-1.vitronectin complex.
    Podor TJ; Shaughnessy SG; Blackburn MN; Peterson CB
    J Biol Chem; 2000 Aug; 275(33):25402-10. PubMed ID: 10821827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?
    Deng G; Curriden SA; Wang S; Rosenberg S; Loskutoff DJ
    J Cell Biol; 1996 Sep; 134(6):1563-71. PubMed ID: 8830783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
    Lobov S; Ranson M
    Cancer Lett; 2011 Apr; 303(2):118-27. PubMed ID: 21316840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction of the cell adhesion molecule CHL1 with vitronectin, integrins, and the plasminogen activator inhibitor-2 promotes CHL1-induced neurite outgrowth and neuronal migration.
    Katic J; Loers G; Kleene R; Karl N; Schmidt C; Buck F; Zmijewski JW; Jakovcevski I; Preissner KT; Schachner M
    J Neurosci; 2014 Oct; 34(44):14606-23. PubMed ID: 25355214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential modulation of cell adhesion by interaction between adhesive and counter-adhesive proteins: characterization of the binding of vitronectin to osteonectin (BM40, SPARC).
    Rosenblatt S; Bassuk JA; Alpers CE; Sage EH; Timpl R; Preissner KT
    Biochem J; 1997 May; 324 ( Pt 1)(Pt 1):311-9. PubMed ID: 9164872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration.
    Zhou A; Huntington JA; Pannu NS; Carrell RW; Read RJ
    Nat Struct Biol; 2003 Jul; 10(7):541-4. PubMed ID: 12808446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.
    Reuning U; Magdolen V; Hapke S; Schmitt M
    Biol Chem; 2003 Aug; 384(8):1119-31. PubMed ID: 12974381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrillar collagen regulation of plasminogen activator inhibitor-1 is involved in altered smooth muscle cell migration.
    Tanaka S; Koyama H; Ichii T; Shioi A; Hosoi M; Raines EW; Nishizawa Y
    Arterioscler Thromb Vasc Biol; 2002 Oct; 22(10):1573-8. PubMed ID: 12377732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis.
    Praus M; Collen D; Gerard RD
    Int J Cancer; 2002 Dec; 102(6):584-91. PubMed ID: 12447999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reciprocal regulation of urokinase receptor (CD87)-mediated cell adhesion by plasminogen activator inhibitor-1 and protease nexin-1.
    Kanse SM; Chavakis T; Al-Fakhri N; Hersemeyer K; Monard D; Preissner KT
    J Cell Sci; 2004 Jan; 117(Pt 3):477-85. PubMed ID: 14679304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The composition of complexes between plasminogen activator inhibitor 1, vitronectin and either thrombin or tissue-type plasminogen activator.
    van Meijer M; Stoop A; Smilde A; Preissner KT; van Zonneveld AJ; Pannekoek H
    Thromb Haemost; 1997 Mar; 77(3):516-21. PubMed ID: 9066004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.